Clinical trials: Plaque
Angina Pectoris, Angina, Unstable
SPECTACL: SPECTroscopic Assessment of Coronary Lipid
The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention…
- Conditions
- Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- SPECTACL (NCT00330928)
- Testing
- Near Infrared Spectroscopy (NIRS) Imaging, intravascular ultrasound (IVUS)
- Where
- 6 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Infraredx
Plaque Psoriasis
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06602219
- Testing
- LY4100511
- Where
- 58 sites in United States, Canada and 5 more
- Volunteers
- 222 people
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Nail Psoriasis, Plaque Psoriasis
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
The purpose of this study is to evaluate if Etanercept administered at a higher initial dose provides greater improvement in nail and skin psoriasis symptoms than a regimen with a lower initial dose.
- Trial name
- NCT00581100
- Testing
- etanercept
- Volunteers
- 136 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Moderate to Severe Plaque Psoriasis
An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
This is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.
- Trial name
- NCT01644396
- Testing
- Adalimumab
- Where
- 7 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).
- Trial name
- NCT03000075
- Testing
- risankizumab
- Volunteers
- 182 people
- Sponsor
- AbbVie
Gingivitis
A Study to Determine the Effects of Adding an Experimental Device With Mouthrinse to Oral Care Regimen
The study will determine the effects of adding mechanical plaque control to a person's oral care regimen. Participants who qualify to participate in the study will will have an equal chance of being assigned to one of three…
- Trial name
- NCT01419626
- Testing
- Interdental cleaning device with water, Interdental cleaning device with essential-oil mouthrinse
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Dental Plaque
Train New Examiners Via Modified Gingival Margin Plaque
The purpose of this study is to train new examiners while testing two commercial products using our standard one-day brushing study regimen by measuring gingival margin plaque index.
- Trial name
- NCT00758563
- Testing
- Fluoride, Triclosan/Fluoride
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Plaque Psoriasis
Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
The purpose of this study was to assess the efficacy and safety of secukinumab at Week 16 based on psoriasis area and severity index (PASI) 75 in subjects who had inadequate response to cyclosporine A.
- Trial name
- NCT02547714
- Testing
- Secukinumab (AIN457)
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03701763
- Testing
- Apremilast (CC-10004)
- Where
- 99 sites in United States, Belgium and 8 more
- Volunteers
- 245 people
- Sponsor
- Amgen
Psoriasis
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).
- Trial name
- VOYAGE 2 (NCT02207244)
- Testing
- Guselkumab 100 mg, Adalimumab
- Where
- 93 sites in United States, Australia and 7 more
- Volunteers
- 992 people
- Sponsor
- Janssen Research & Development, LLC
Keloid, Alopecia Areata
Pain Outcomes Following Intralesional Corticosteroid Injections
Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics.
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar
- Trial name
- NCT03630198
- Testing
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Coronary Artery Disease, Atherosclerosis
Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions
Rotational atherectomy is an established tool to treat blocked arteries in the heart, in which the blockage is due to significant amounts of calcified material.
- Trial name
- ROTA-CUT (NCT04865588)
- Testing
- rotational atherectomy, cutting balloon, plain old balloon
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Samin Sharma, M.D., F.A.C.C., M.S.C.A.I.
Psoriasis
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for…
- Trial name
- NCT03875508
- Testing
- Risankizumab, Autoinjector
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis
This trial will be a double-blind, multi-center, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of SAN021 study drug when administered for up to 42 days to adults between the ages of 18 to…
- Trial name
- NCT03000608
- Testing
- SAN021 Serum
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Santalis Pharmaceuticals, Inc.
Psoriasis
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
The purpose of this study is to evaluate the efficacy of adding methotrexate to etanercept compared with etanercept monotherapy as measured by the percentage of participants achieving a 75% improvement from baseline in the…
- Trial name
- NCT01001208
- Testing
- Methotrexate, Etanercept
- Volunteers
- 478 people
- Sponsor
- Amgen
Plaque Psoriasis
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.
- Trial name
- PROSE (NCT02752776)
- Testing
- Secukinumab
- Where
- 215 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 1,660 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
The purpose of this study is to evaluate radiolabeled [18F]MK-3328 as a PET tracer for estimating the regional distribution and extent of amyloid plaques in participants suffering from amnestic mild cognitive impairment (aMCI)…
- Trial name
- NCT01385033
- Testing
- [18F]MK-3328
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Gingivitis
Curved Soft-Picks on Plaque Accumulation on Patients With Gingivitis
The aim of this study is to evaluate the efficacy of a new interdental cleaning device (Soft-Picks Advanced), as compared to a leading brand floss; and, how ease of use can promote the establishment of a hygienic routine of…
- Trial name
- NCT02883244
- Testing
- Soft-Picks Advanced, Floss
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sunstar Americas
Plaque Psoriasis, Non-alcoholic Fatty Liver Disease
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study was to assess the therapeutic efficacy of secukinumab on the psoriatic skin and to explore the anti-inflammatory (reduction of hepatic inflammation and cell damage), anti-steatotic (reduction of hepatic…
- Trial name
- pINPOINt (NCT04237116)
- Testing
- Investigational Arm - secukinumab
- Where
- 8 sites in Germany, Spain
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered…
- Trial name
- IPSI-PSO (NCT02595970)
- Testing
- Secukinumab
- Where
- 17 sites in France
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals